Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

NCT07706179 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

HR+/HER2+ Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Alisertib

Sponsor

University of Wisconsin, Madison